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HO ET AL. : Angioplasty for Long Diffuse Coronary Lesions. Long diffuse coronary artery stenosis is often
encountered in elderly patients. Many of these patients have multivessel disease, previous myocardial infarction,
diabetes and impaired left ventricular function. Due to a combination of diffuse disease, small caliber vessels and
often heavy calcification, bypass graft surgery for such vessels is associated with poor short and long-term outcomes.
By virtue of their length, long lesions often involve a multiple number of side branches or significant side branches,
angulated segments, tapered segments and small caliber terminal branches. As a result, angioplasty for long diffuse
lesions is associated with a slightly higher in-hospital complication rate and poorer long-term outcome. Despite the
development of coronary stenting over the last decade, PTCA for long diffuse lesions remains problematic. Due to
the nature of the disease, there is a higher risk of stent thrombosis and in-stent restenosis. Current approaches
include the use of long balloons, rotational atherectomy, laser angioplasty, and a combination of primary or bail-out
spot stenting. (J HK Coll Cardiol 2000;8:129-137)
Coronary Angioplasty, Long Diffuse Lesions

Introduction
Long diffuse lesions are commonly encountered
in patients with coronary artery disease, representing
around 20% of contemporary interventional practice.
With advances in percutaneous transluminal coronary
angioplasty (PTCA) hardware, imaging equipment and
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operator experience, an increasing number of complex
coronary lesions are now being treated with a higher
procedural success rate and lower in-hospital
complication rate. Long diffuse lesions, however,
remain a challenge to the interventionist because of a
higher procedural complication rate and poorer longterm outcome compared to the "ideal" lesions.
Historically, even lesion length >10 mm has been
associated with increased morbidity and mortality.1,2 Not
uncommonly, long diffuse lesions are found in patients
with multivessel disease, particularly in the elderly and
those with diabetes mellitus.3,4
During the mid 1980's, the American College of
Cardiology/American Heart Association (ACC/AHA)
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Task Force classified coronary lesions into three
risk groups based on lesion morphology and
characteristics. 5 Lesion length was considered an
important variable in predicting risk associated with
PTCA. Type A lesions are <10 mm in length. Such
lesions are associated with the lowest risk and highest
success rate. Type B lesions are those between 10-20
mm in length and are considered to have an intermediate
risk and success rate. Type C lesions include lesions >
20 mm in length and are associated with the highest
risk and the lowest success rate.
Despite the development of coronary stenting
over the last decade, PTCA for long diffuse lesions is
still problematic due to a higher risk of stent thrombosis
as a result of the small caliber diffuse disease vessels
with excessive metal surface area. Most importantly,
the use of multiple stents or long stents may result in a
higher incidence of in-stent restenosis.4

Balloon Angioplasty for Long Lesions
During the 1980's, when the standard 20 mm
length balloons were used, PTCA for long diffuse
lesions was associated with excessive complication and
low procedural success rates. Ghazzal et al described
their experience of PTCA for a cohort of 181
consecutive patients with lesions >20 mm in length
treated between January 1986 and December 1989.6
Using standard length (20 mm) angioplasty balloons,
the primary success rate was only 85.8%. There was
also a significant incidence of arterial complications
and emergency surgery. Meier et al also noted an
increase in complications associated with angioplasty
of long lesions.7
Increased balloon length has been proposed for
long diffuse lesions. In a small randomised study of 44
patients, Brymer et al compared the effects of long
(33 mm) vs standard-length (20 mm) balloons in patients
with tandem lesions or lesions measuring 15-25 mm in
length. The group treated with long balloons required
fewer inflations and had a lower incidence of intimal
dissection compared to the standard balloon group.
(4/22 vs 12/22).8 Savas et al used long balloons to treat
109 lesions >20 mm in length (mean 38 mm). They
reported a relatively high success rate (90%) and low
major complication rate (2%).9 Despite these reports,
which have mostly been descriptive series using
J HK Coll Cardiol, Vol 8

historical controls, there is relatively little data from
controlled or randomised series documenting the
advantage of long vs short/standard PTCA balloons in
long diffuse lesions.
Nevertheless, one can avoid multiple, repeated,
and fragmented dilatations across the diseased vessel
segment by using a long balloon. 30 and 40 mm long
balloons are now readily available in most interventional
suites. Theoretically, the longer balloons are more
conforming to vessel curvature and produce a more
gradual pressure distribution to the arterial wall,
resulting in a more gradual transition in arterial stretch.
The use of long balloons, however, has its own
disadvantage. Firstly, long balloons are more prone to
rupture. In patients with diffuse disease, particularly in
heavily calcified vessels, high inflation pressure is often
required to fully expand the lesion. In this context, the
balloon may either rupture or create dissection at its
two shoulders as a result of over-expansion in the
relatively normal vessel segments at both ends of the
lesion.
In vessels that taper over a 30-40 mm segment
[e.g. the left anterior descending artery (LAD)],
dilatation with a tapered balloon or 2 standard-length
balloons with different size or dilatation pressures may
be less traumatic compared to a single dilatation with a
long, non-tapered balloon (Figure 1).

Complications
By virtue of their length, long lesions often
involve a multiple number of side branch or significant
side branches, angulated segments, tapered segments
and small caliber terminal branches [as in the case of
distal right coronary artery (RCA) lesions involving the
posterior descending artery]. These are all factors
potentially contributing to increased complications
associated with PTCA.
In the 1985-1986 National Health, Lung and Blood
Institute (NHLBI) Registry, diffuse and multiple discrete
lesions were found to be a significant morphological
predictor of acute closure, occurring in 8.5% of those
with diffuse disease vs 3.3% of those with single,
discrete lesions.10 Ellis et al retrospectively analyzed
4,772 PTCA procedures performed between 1982 and
1986 and found that lesion length ≥2 times vessel
diameter was an independent predictor of acute closure.2
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Figure 1. A 56-year-old male with a diffusely diseased LAD (arrows) before and after balloon-only angioplasty
with a 2.0 × 20 mm balloon.

Report from a series of 552 patients from the
thoraxcenter undergoing conventional PTCA in 1991
and 1992 has also confirmed the ACC/AHA
morphologic stratification in predicting procedural
success and complication rates.11 The success rates were
94.5%, 88.8% and 56.4% for Types A, B and C lesions
respectively. The corresponding complication (abrupt
closure, surgery or death) rates were 1.2%, 3.7% and
12.8%.
Unfortunately, patients with long diffuse disease
are often poor candidates for coronary bypass surgery.
These patients are often elderly and/or diabetic. Many
have previous myocardial infarction (MI) and impaired
left ventricular function. Due to a combination of diffuse
disease, multiple lesions in the same vessel, small
caliber vessels and, often, heavy calcification, coronary
artery bypass graft surgery (CABG) for such vessels is
associated with poor short and long-term outcomes.
Although endarterectomy combined with CABG may
be used as an alternative, it has been associated with a
marked increase in morbidity and mortality compared
with CABG alone.12

Multi-Hospital Eastern Atlantic Restenosis Trial (MHEART) Group obtained follow-up angiography in 510
patients enrolled in a controlled trial of the effects of
methylprednisolone on restenosis after coronary
angioplasty. Of the 598 successfully dilated coronary
lesions analyzed, the strongest univariate relations to
restenosis rate were found for lesion location, lesion
length, percentage stenosis before and after PTCA, and
vessel diameter. Lesions ≤4.6 mm in length had a
significantly lower restenosis rate compared to those
>4.6 mm in length (33% vs 45%, P = 0.001).14
Bourassa et al reported a 58% angiographic
restenosis rate for lesions >10 mm in length compared
with 32% for lesions <10 mm in length.16 Despite the
use of long balloons, long lesions are associated with a
higher restenosis rate. In a series treated with long
balloons at the Duke University, the angiographic
restenosis rate was 57% at follow-up. Fortunately, when
restenosis occur following PTCA for long lesions, the
restenotic segments tend to be shorter and can be easily
redilated. In the Duke University series, the mean
restenotic lesion length was only 7 mm compared with
the original mean lesion length of 17.6 mm.17

Restenosis Rate
Stenting for Long Diffuse Lesions
Lesion length has been reported to be one of the
angiographic factors associated with restenosis.13-15 The
131
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over the last decade have demonstrated that coronary
stents can improve short and long-term outcome for a
variety of lesion types, including de novo lesions,
restenotic lesions, total occlusions, and saphenous vein
graft stenosis, 18-21 the role of coronary stenting for
patients with long diffuse lesions remains unresolved.
In the past, treatment of long lesions with stenting
was unpopular because of a relatively high risk of stent
thrombosis, particularly when multiple stents were
used.22,23 Another factor discouraging interventionists
from stenting long diffuse lesions was the high
restenosis rate of up to 70% with the use of multiple
stents in early series.24-26
With advances in anti-platelet regimes, stent
deployment techniques, stent-catheter delivery systems
and stent design, short and long-term results of coronary
stenting have improved significantly over the last
decade. With these advances, several recent studies have
suggested that coronary stenting may be a promising
treatment for long diffuse disease. Kornowski et al27
examined acute and long-term outcomes in 117 patients
treated with ≥3 contiguous stents in a single coronary
vessel during 1994-1995. Overall procedural success
in the absence of death, acute MI, or emergency CABG
was 97.4%. The incidence of repeat target vessel
revascularisation at 1 year was only 13.3%. These
results compare favorably with those for patients with
focal lesion and those treated with ≤2 stents. In another
study, from June 1993 to December 1995, 47
consecutive patients were implanted with ≥4 (mean
4.5 ± 1, range 4-7) stents to cover ≥2 adjacent diseased
native coronary segments. 28 Despite the long length
(63 ± 20 mm) of the lesions treated, angiographic
success in the absence of major complications was
achieved in 96%. Long-term follow-up at 430 ± 199
days was completed in all patients. Seventy-six percent
of the patients were asymptomatic. Three patients
underwent CABG while 13 patients (28%) underwent
repeat angioplasty.
In a prospective registry of 187 patients who
underwent PTCA with the long (32 mm) NIR ®
(SCIMED, Boston Scientific International, B.V.,
France) stent, a high procedural success rate (93%) with
a low major complication rate was reported. At 6-month
follow-up, the clinical event rate was 8.5%, target lesion
revascularisation (TLR) was 6% and angiographic
restenosis rate was 27%.29
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Caution, however, should be exercised in
interpreting such descriptive series. To date, few
randomised stent trials have included patients with long
lesions. The relatively high success rate and low repeat
revascularisation rate could be due to selection bias such
as the exclusion of patients with small or highly tortuous
vessels. Moreover, multiple stenting for long diffuse
lesions is also costly.
In a recent analysis on 1,090 lesions in 725
patients, the restenosis rates for stented segment length
≤20 mm; length >20 but ≤35 mm; and length >35 mm
were 23.9%, 34.6% and 47.2% respectively. 30
Kobayashi et al compared follow-up results of the short
and long NIR® stents with the Palmaz-Schatz® (PS)
(Cordis a Johnson & Johnson, FL, USA) stent. 31
Restenosis rates were 16.5% in lesions with a PS stent,
13.3% in those with a 16 mm NIR® stent and 47.4% in
those with a 32 mm NIR® stent. Thus, long stented
segment is an independent predictor of restenosis, and
a more selective approach is recommended.
Balloon angioplasty ± bail out stenting probably
remains the most popular form of approach currently
adopted by interventionists for long diffuse lesions.
Currently available data do not yet support a strategy
of elective stenting for diffuse coronary lesions. Recent
studies with a focus on balloon angioplasty with
"provisional stenting" have suggested a reasonably low
restenosis rate and, possibly similar rates of repeat
revascularisation compared to elective stenting.

Excimer Laser Angioplasty in
Long Lesions
Laser angioplasty has been attempted for diffuse
stenosis but have failed to demonstrate any advantage
over balloon angioplasty alone with respect to the initial
and long-term clinical and angiographic outcome. In a
randomised trial of excimer laser angioplasty vs balloon
angioplasty in 308 patients with stable angina and
coronary lesions >10 mm in length, there was no
difference in the angiographic success rate (80% vs
79%), MI (4.6% vs 5.7%), CABG (10.6% vs 10.8%),
and repeat angioplasty rates during 6 months of followup (21.2% vs 18.5%) between the laser group and the
balloon group. The restenosis rate was 51.6% in the
laser group vs 41.3% in the balloon group.32 Of note
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was that 98% of the laser angioplasty procedures were
followed by balloon angioplasty.
The European Coronary Excimer Laser
Angioplasty Registry evaluated the clinical and
angiographic outcome of 470 patients who underwent
laser angioplasty from January 1991 to January 1993.33
Failure occurred in 56 (12%) interventions. By
multivariate analysis, the strongest predictor of failure
was the intention to treat long segmental lesions.
Complications in this study included acute closure
(7.8%), perforation (1.9%), MI (2.1%), CABG (1.9%)
and mortality (1.5%). In the Excimer Laser Coronary
Angioplasty (ELCA) Registry involving 3,000
consecutive patients, procedural success was 90%.
Contrary to the findings of Baumbach et al, there was
no significant difference in success or complication rates
with respect to lesion length.34 Twenty percent of the
lesions treated in the ELCA Registry were >20 mm in
length. No significant differences in success rates or
major complications were detected between lesions
<10 mm, 10-19 mm, 20-29 mm, and >30 mm in length.
However, coronary perforation occurred in 1.2% of the
patients, even though this dropped to 0.4% in the last
1,000 patients. In the ELCA registry, the overall
restenosis rate was 46%, increasing to 59% for lesions
>10 mm in length.35
In a more recent study, 215 patients with 244
lesions were prospectively randomised at 14 clinical
centers to laser vs stand-alone PTCA. After laser
treatment, all patients underwent balloon PTCA.
Although procedural success rate was similar in the two
groups, the use of laser vs PTCA alone resulted in more
major and minor complications (18.0% vs 3.1%), MI
(4.3 vs 0%), death (1.7% vs 0%), and major adverse
events (10.3% vs 4.1%). Around 42% of the lesions
treated in this study were >10 mm in length. Although
there is no subgroup analysis for long lesions, it would
appear that there is no overall immediate or long-term
benefit for laser angioplasty over stand-alone PTCA.36
In a more recent report based on the European Registry,
the laser group, when compared to the PTCA group,
was associated with an unfavorable clinical outcome in
patients with long (>20 mm) lesions, calcified lesions,
small vessels (≤2.5 mm), or total coronary occlusions.
Clinical outcome was worse in patients with tandem
lesions treated with laser compared to balloon
angioplasty (9/18 vs 3/26 lesions).37
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Rotational Atherectomy in
Long Lesions
Long lesions are also associated with a lower
primary success rate, a higher in-hospital complication
rate and higher restenosis rate compared to short lesions
when high-speed rotational atherectomy is applied. The
"slow flow" phenomenon, a complication associated
with rotablation, has been observed more often amongst
long lesions. Predictors of "slow flow" include long
lesions combined with diffuse disease (plaque burden),
small caliber and limited distal runoff. 38 In the
Rotablator Multicenter Registry, of 143 lesions
15-25 mm in length, procedural success was achieved
in 92%. However, these lesions were associated with a
higher incidence of Q and non-Q MI (2.8% and 6.2%)
compared with lesions of <10 mm in length (0.7% and
4.0% respectively).39 In a report by Teirstein et al using
the rotablator in a small cohort of patients not suitable
for balloon angioplasty, where 3/4 of the patients had
diffuse disease defined as stenosis >10 mm in length,
procedural success was achieved in only 70% of the
patients with long lesions as oppose to 92% of the
patients with lesions <10 mm in length. Non-Q MI
occurred in 19% of the patients and was associated with
longer lesions. Angiographic follow-up at 6 months also
showed a higher restenosis rate (75% vs 22%) for lesions
>10 mm vs lesions <10 mm in length.40
Few reports have specifically compared
restenosis rate between rotablator and conventional
PTCA for long lesions. Large descriptive series which
included both long and short lesions have so far failed
to demonstrate any clear-cut advantage of rotational
atherectomy over conventional PTCA in terms of
restenosis rate during long term angiographic follow
up.41 Brown et al reported the 1 year follow-up results
in 525 patients with 670 lesions treated with rotablation
by the New Approaches to Coronary Intervention
(NACI) investigators.42 Overall, TLR was required in
27% of the patients. At one year, 30% had experienced
death, Q-MI, or TLR, and long lesions was one of the
independent predictor of events. Although not reported
separately, the TLR for long lesions would be much
higher than the 27% reported for the entire cohort. In
the Rotational Atherectomy Multicenter Registry,
6-month angiographic follow-up result was available
on 64% of 874 lesions treated. The overall restenosis
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rate of 38% appears similar to other techniques. 41
Kobayashi et al reported their results on 162 lesions in
126 who underwent rotational atherectomy followed by
stenting between May 1995 and February 1997. Despite
stenting, the restenosis rates still ranged from 31% to
50%, depending on the final burr size and final burr:
vessel ratio.43

Our Experience in Managing Long
Diffuse Lesions
Between September 1997 and August 1999,
consecutive patients who underwent an elective first or
repeat angioplasty by our university team were
analyzed. The indication for angioplasty included stable
angina, unstable angina and post-MI angina. A total of
409 lesions in 349 patients were evaluated (Table 1).
Adjunctive devices ( rotational athrectomy) was used
in 2% of the cases. No ELCA was used in this series.
Patients were divided into Group I (lesion length
≤20 mm) and Group II (lesion length >20 mm). Mean
lesion length was 27 mm in Group II vs 11 mm in Group
I. There were significantly more patients with triple
vessel disease in Group II. There were slightly more
patients with hypertension, diabetes, and

hyperlipidermia in Group II compared to Group I,
although this did not reach statistical significance.
There was no difference between the two groups
with regard to in-hospital complication. Procedural
success, defined as residual stenosis of <30% without
any in-hosptial death, CABG or MI, was significantly
higher for Group I compared to Group I in (97% vs
87.5%). During follow-up at a mean of 13 ± 5 months,
event-free survival was significantly lower in Group II
compared to Group I (78.6% vs 87.8%) (Table 2).
Significantly more patients in Group II developed
recurrent angina, requiring repeat catheterisation and
TLR (21.5% vs 9.7%) (Figures 2 and 3).

Current Approach to Long Lesions
With improvement in intravascular ultrasound
(IVUS) software and hardware, interventionists can now
make a more rational decision on their choice of
adjunctive devices in dealing with long diffuse lesions.
In our practice, the rotablator is generally reserved for
heavily calcified lesions where the PTCA balloon may
not cross and for lesions that do not yield to balloon
dilatation. For closely-located tandem lesions or long
lesions with little tapering, our approach is to use a

Table 1. Baseline clinical and angiographic characteristics

Age
Male
Hypertension
Diabetes
Hyperlipidemia
Triple vessels disease
Mean reference diameter (mm)
Mean lesion length (mm)
Procedural success
Stenting performed:
No. of stents
Mean stent length (mm)
Complication:
Death
CABG
Q-MI

Group I
≤20 mm (n=297)
62.39 ± 7.59
242 (81.5%)
178 (57.1%)
84 (28.3%)
188 (63.3%)
45 (15.2%)
3.1 ± 0.4
10.8 ± 3.2
288 (97.0%)

Group II
>20 mm (n=112)
63.11 ± 7.74
89 (79.5%)
68 (60.7%)
38 (33.9%)
78 (69.6%)
35 (31.3%)
3.0 ± 0.3
26.8 ± 5.6
98 (87.5%)

208 (70.0%)
16 ± 3.1

74 (66.1%)
23.2 ± 5.7

0
1 (0.3%)
3 (0.9%)

0
0
1 (0.1%)

P
ns
ns
ns
ns
< 0.001

< 0.0001

ns
ns

ns = not significant
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Table 2. Clinical outcome during follow-up at 13 ± 5 months

Patients at follow-up
TLR
Death of any cause
MI (Q or Non-Q)
Event-free survival

Group I
≤20 mm (n = 297)
281 (94.6%)
27 (9.7%)
1 (0.3%)
0 (0%)
261 (87.8%)

Group II
>20 mm (n = 112)
108 (96.4%)
21 (21.5%)
1 (0.9%)
1 (0.9%)
88 (78.6%)

P
0.007
ns
ns
0.018

ns = not significant

Figure 2. A 62-year-old man with triple vessel disease and old inferior Q-MI. The LAD is diffusely diseased
from the proximal to mid-segments (arrows). Following stenting with two 3.0 × 20 mm balloon-expandable coil
stents, there was no significant residual stenosis.

Figure 3. A 68-year-old man with triple vessel disease and previous MI underwent staged PTCA to his RCA. The RCA
was diffusely diseased in the proximal and mid-segments (arrows). Following the deployment of two balloon-expandable
slotted-tube stents (3.5 × 23 mm; 3.5 × 18 mm), there was no significant residual stenosis.
135
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30 mm to 40 mm long balloon. For multiple discrete
lesions, particularly when the relatively "disease-free"
segments (those <60% stenosis) involve significant side
branch (such as the diagonal branch in a diffusely
diseased LAD), our approach is to use a standard-length
(20 mm) balloon or even a short (15 mm) balloon for
initial dilatation of those discretely diseased segments.
In such situations, non-overlapping, short, or standard
length stents are used to cover only those areas with
suboptimal angiographic results or those vital areas (eg.
proximal LAD) that have been dilated with a balloon.
Some operators may prefer "spot-stenting", covering
only those areas with significant dissection or residual
stenosis. Other operators would cover the entire diseased
segment. If possible, one should resist the temptation
to dilate non-critical lesions, reserving the use of long
stents or overlapping stents for suboptimal angiographic
results or for long dissection. One should not forget that
CABG still plays an important role in the management
of long diffuse lesions where the distal vessel is graftable
and especially in diabetics with multivessel disease.
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